Sangamo Therapeutics, Inc.

DB:GBY Stock Report

Market Cap: €247.4m

Sangamo Therapeutics Valuation

Is GBY undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of GBY when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Discounted Cash Flow
Simply Wall St
€71.40
Fair Value
98.5% undervalued intrinsic discount
6
Number of Analysts

Below Fair Value: GBY (€1.08) is trading below our estimate of fair value (€71.4)

Significantly Below Fair Value: GBY is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for GBY?

Key metric: As GBY is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for GBY. This is calculated by dividing GBY's market cap by their current revenue.
What is GBY's PS Ratio?
PS Ratio4.6x
SalesUS$52.29m
Market CapUS$253.51m

Price to Sales Ratio vs Peers

How does GBY's PS Ratio compare to its peers?

The above table shows the PS ratio for GBY vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average9x
HPHA Heidelberg Pharma
14x16.6%€118.4m
FYB Formycon
18.2x24.6%€1.1b
BIO3 Biotest
1.5x3.6%€1.4b
MDG1 Medigene
2.1x16.4%€15.9m
GBY Sangamo Therapeutics
4.6x40.9%€253.5m

Price-To-Sales vs Peers: GBY is good value based on its Price-To-Sales Ratio (4.6x) compared to the peer average (9x).

Price to Sales Ratio vs Industry

How does GBY's PS Ratio compare vs other companies in the DE Biotechs Industry?

5 CompaniesPrice / SalesEstimated GrowthMarket Cap
CNW co.don
0.7xn/aUS$6.97m
V9Z Aceragen
0.4xn/aUS$3.12m
PA8 Paion
0.2x30.2%US$2.78m
V9Z Aceragen
0.3x-161.8%US$2.18m
GBY 4.6xIndustry Avg. 8.0xNo. of Companies5PS0612182430+
5 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: GBY is good value based on its Price-To-Sales Ratio (4.6x) compared to the European Biotechs industry average (8.2x).

Price to Sales Ratio vs Fair Ratio

What is GBY's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

GBY PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio4.6x
Fair PS Ratio3.2x

Price-To-Sales vs Fair Ratio: GBY is expensive based on its Price-To-Sales Ratio (4.6x) compared to the estimated Fair Price-To-Sales Ratio (3.2x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst GBY forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€1.08
€5.31
+390.3%
60.1%€9.65€1.93n/a6
Jan ’26€2.47
€5.31
+114.7%
60.1%€9.65€1.93n/a6
Dec ’25€2.10
€5.87
+179.6%
51.4%€9.47€1.89n/a5
Nov ’25€1.62
€3.52
+116.8%
65.3%€7.41€0.93n/a5
Oct ’25€0.73
€3.48
+376.5%
65.3%€7.32€0.92n/a5
Sep ’25€0.71
€3.48
+389.1%
65.3%€7.32€0.92n/a5
Aug ’25€0.58
€3.51
+502.1%
65.3%€7.39€0.92n/a5
Jul ’25€0.31
€3.22
+937.5%
67.5%€7.36€0.92n/a6
Jun ’25n/a
€3.22
0%
67.5%€7.36€0.92n/a6
May ’25€0.44
€3.22
+633.8%
67.5%€7.36€0.92n/a6
Apr ’25€0.57
€3.22
+466.8%
67.5%€7.36€0.92n/a6
Mar ’25€1.00
€2.96
+197.4%
71.6%€7.48€0.94n/a6
Feb ’25n/a
€2.96
0%
71.6%€7.48€0.94n/a6
Jan ’25€0.50
€2.96
+488.6%
71.6%€7.48€0.94€2.476
Dec ’24€0.38
€2.96
+682.3%
71.6%€7.48€0.94€2.106
Nov ’24€0.55
€6.21
+1,031.3%
33.2%€9.44€3.40€1.628
Oct ’24€0.51
€5.51
+971.7%
43.3%€9.17€1.38€0.739
Sep ’24€0.83
€5.51
+562.4%
43.3%€9.17€1.38€0.719
Aug ’24€1.14
€6.80
+495.6%
54.7%€14.74€1.38€0.589
Jul ’24€1.09
€6.80
+523.1%
54.7%€14.74€1.38€0.319
Jun ’24€1.00
€6.80
+580.8%
54.7%€14.74€1.38n/a9
May ’24€1.42
€7.64
+437.9%
58.2%€14.58€1.37€0.449
Apr ’24€1.59
€10.39
+555.1%
39.2%€14.75€3.87€0.578
Mar ’24€2.72
€11.59
+326.5%
48.3%€23.45€3.94€1.009
Feb ’24€3.13
€12.00
+283.0%
56.0%€23.49€3.76n/a9
Jan ’24€2.85
€12.86
+351.7%
52.5%€23.52€3.76€0.509
Analyst Price Target
Consensus Narrative from 6 Analysts
€5.11
Fair Value
78.8% undervalued intrinsic discount
6
Number of Analysts

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/10 04:24
End of Day Share Price 2025/01/10 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Sangamo Therapeutics, Inc. is covered by 24 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Huidong WangBarclays
Gregory HarrisonBofA Global Research
Jonathan AschoffBrean Capital